Health Condition 1: null- Hypertension with Cardiovascular Disease
Conditions
Interventions
Intervention1: Olmax-M [Olmesartan (20mg) and Metoprolol succinate ER (25mg)] Tablet and Olmesartan (20mg) and Metoprolol succinate ER (50mg) Tablet: Olmax-M [Olmesartan (20mg) and Metoprolol succinat
Sponsors
Glenmark Pharmaceuticals Limited
Eligibility
Inclusion criteria
Inclusion criteria: ? All CVD patients (prior MI, ACS, PCI, CABG) with hypertension OR ? All CVD patients (prior MI, ACS, PCI, CABG) with Uncontrolled hypertension (BP > 140/90 mmHg for hypertensive patients and BP > 130/80 mmHg for hypertensive patients with Diabetes or renal disease).
Exclusion criteria
Exclusion criteria: ? Not willing to provide written informed consent and comply with the protocol ? Age below 18 years and above 65 years ? Secondary hypertension ? Patients requiring concomitant anti-hypertensive medications other than angiotensin receptor blockers (ARBs) or Metoprolol ? Uncontrolled diabetes mellitus ? Baseline laboratory values outside the clinically acceptable limits ? Pregnant women and lactating mothers ? Females of child bearing age not practicing contraception or not willing to use barrier contraceptive ? Known hypersensitivity to Olmesartan/Metoprolol ? Patients with effort angina more than class II (Drugs like Nitrates, ranolazine or Trimetazidine can be used but not amlodipine or nicorandil). ? Sick sinus syndrome or Atrioventricular block or Heart Failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Magnitude of systolic and diastolic blood pressure reduction from baseline at end of 8 weeks of treatment Percent of subjects reaching blood pressure target of 140/90 mmHg in hypertensive patients and 130/80mmHg in hypertensive patients with diabetes and renal disease at end of 8 weeks of treatment Timepoint: End of 8 weeks of treatment | — |
Countries
India
Contacts
Public ContactProf Dr JC Mohan
President of the Indian Society of Interventional Cardiology
Outcome results
None listed